Effect of N-Acetylcystein on Butyrate-Treated Chinese Hamster Ovary Cells To Improve the Production of Recombinant Human Interferon-β-1a

2008 ◽  
Vol 21 (4) ◽  
pp. 1154-1164 ◽  
Author(s):  
Han Kyu Oh ◽  
Moon Kyoung So ◽  
Jihye Yang ◽  
Ho Chul Yoon ◽  
Ji Soo Ahn ◽  
...  
1995 ◽  
Vol 48 (6) ◽  
pp. 639-648 ◽  
Author(s):  
Andrew D. Hooker ◽  
Merlin H. Goldman ◽  
Nicola H. Markham ◽  
David C. James ◽  
Andrew P. Ison ◽  
...  

1992 ◽  
Vol 39 (3) ◽  
pp. 327-335 ◽  
Author(s):  
Paul M. Hayter ◽  
Elisabeth M. A. Curling ◽  
Anthony J. Baines ◽  
Nigel Jenkins ◽  
Ian Salmon ◽  
...  

Pathology ◽  
1993 ◽  
Vol 25 (3) ◽  
pp. 268-276 ◽  
Author(s):  
Wanda B. Mackinnon ◽  
Marlen Dyne ◽  
Rebecca Hancock ◽  
Carolyn E. Mountford ◽  
Adrienne J. Grant ◽  
...  

Author(s):  
Shazid Md. Sharker ◽  
Md. Atiqur Rahman

Most of clinical approved protein-based drugs or under in clinical trial have a profound impact in the treatment of critical diseases. The mammalian eukaryotic cells culture approaches, particularly the CHO (Chinese Hamster Ovary) cells are mainly used in the biopharmaceutical industry for the mass-production of therapeutic protein. Recent advances in CHO cell bioprocessing to yield recombinant proteins and monoclonal antibodies have enabled the expression of quality protein. The developments of cell lines are possible to upgrade specific productivity. As a result, it holds an interesting area for academic as well as industrial researchers around the world. This review will concentrate on the recent progress of the mammalian CHO cells culture technology and the future scope of further development for the mass-production of protein therapeutics.


Sign in / Sign up

Export Citation Format

Share Document